All In Biotech

NDA 217722 · Harm Reduction Therp

Rivive

Naloxone Hydrochloride · Nasal

Priority review

Last checked: Nov 19, 2026Latest source record: Jul 28, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations

First approved

2023

Jul 28, 2023

Approved uses

1

Original approval plus efficacy supplements

Registered trials

682

129 Phase 3, 31 recruiting

FAERS reports

934

753 serious, 140 with death reported

AI brief across all sources

Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.

What it is approved for

From the label in effect Jan 13, 2026.

Uses • to “revive” someone during an overdose from many prescription pain medications or street drugs such as heroin • this medicine can save a life

Approval history

Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.

  • Jul 28, 2023 Original approval · Type 5 - New Formulation or New Manufacturer · priority review LabelLetterReview
1 products under this application
  • RIVIVE · NALOXONE HYDROCHLORIDE 3MG/SPRAY · SPRAY, METERED, NASAL · Over-the-counter

Clinical trials

Interventional ClinicalTrials.gov studies with "Naloxone" as an intervention, any sponsor and status, largest first.

All 682 trials

Most reported adverse reactions

FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.

Signals
  • drug ineffective97
  • toxicity to various agents90
  • vomiting58
  • fatigue49
  • off label use49
  • overdose48
  • drug withdrawal syndrome46
  • nausea46
  • diarrhoea40
  • pain40
  • febrile neutropenia32
  • fall31

FAERS reports by year

By the date FDA received the report.

View as table
YearReports
20041
20051
20072
20083
200910
20108
20113
20129
20139
201410
201515
201626
201735
201859
201950
2020128
202185
2022106
202394
2024117
2025103
202660

Recalls

0 FDA enforcement reports for this application.

No recalls on record for this application.

Shortages

FDA's drug shortage list.

Not on FDA's shortage list.

Medicare spending

CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.

Compare

Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.

Published evidence

PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.

All 1,733 on PubMed

Sponsor: Harm Reduction Therp

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.